Prosecution Insights
Prosecution Insights
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 2 | 50.0% | +53.3% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.7% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265186 | PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | SEITZ, ANTHONY JOSEPH | 22d overdue |
| 17631773 | COMPOSITION COMPRISING STEROL DERIVATIVES FOR USE IN THE TREATMENT OF A NEURONAL PATHOLOGY RELATED TO HYPOXIA, HYPOGLYCEMIA AND/OR HYPERGLYCEMIA | KUCKLA, ANNA GRACE | 22d overdue |
| 18034317 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265186 | PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | SEITZ, ANTHONY JOSEPH | 1629 | §112Other | Final Rejection | 22d overdue | Pending | Jun 02, 2023 |
| 18034317 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | 1626 | §103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 17631773 | COMPOSITION COMPRISING STEROL DERIVATIVES FOR USE IN THE TREATMENT OF A NEURONAL PATHOLOGY RELATED TO HYPOXIA, HYPOGLYCEMIA AND/OR HYPERGLYCEMIA | KUCKLA, ANNA GRACE | 1626 | Other | Final Rejection | 22d overdue | Pending | Jan 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial